Search

Displaying results 7191 - 7200 of 10000 in total
  1. Drug

    Oxidronic acid

    go.drugbank.com/drugs/DB14159
    Approved

  2. Drug

    NM3086

    go.drugbank.com/drugs/DB17719
    Experimental

    NM3086 is a recombinant, humanized, aglycosylated, IgG1-kappa anti-properdin monoclonal antibody being developed by Novelmed Therapeutics Inc.[L46193]

  3. Drug

    Varlilumab

    go.drugbank.com/drugs/DB11930
    Investigational

    Varlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.

    Categories: Amino Acids, Peptides, and Proteins
  4. Drug

    Gam-COVID-Vac

    go.drugbank.com/drugs/DB15848
    Investigational

    Gam-COVID-Vac was created by Gamaleya Research Institute of Epidemiology and MIcrobiology in Russia. … in June 2020, and were completed in early August 2020.

  5. Drug

    PRX-07034

    go.drugbank.com/drugs/DB05993
    Experimental

  6. Drug

    INZ-701

    go.drugbank.com/drugs/DB17629
    Investigational

    INZ-701 is an enzyme replacement therapy under development with the intention to be used for the treatment of calcification disorders of the circulatory system, bones, and kidneys.

    Synonyms: Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IGG1 (INZ-701)
  7. Drug

    SRT-1720

    go.drugbank.com/drugs/DB17057
    Experimental

    SRT-1720 is an activator of NAD(+)-dependent histone deacetylase SIRT1.[A253147]

    Synonyms: 2-quinoxalinecarboxamide, n-(2-(3-(1-piperazinylmethyl)imidazo(2,1-b)thiazol-6-yl)phenyl)-, N-(2-(3-(1-piperazinylmethyl)imidazo(2,1-b)thiazol-6-yl)phenyl)-2-quinoxalinecarboxamide
  8. Drug

    MD05

    go.drugbank.com/drugs/DB06375
    Investigational

    MD05 is a beta-tricalcium phosphate (beta-TCP) coated with recombinant human growth/differentiation factor-5 (rhGDF-5).

  9. Drug

    Bromperidol

    go.drugbank.com/drugs/DB12401
    ApprovedWithdrawn

    Bromperidol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders, among others.

  10. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).